What is the position of pulmonary arterial hypertension-specific drug therapy in patients with Eisenmenger syndrome: A systematic review and meta-analysis
| Autor: | Tie-Wei Lu, Qiang Li, Hong-Yu Kuang, Yu-Hao Wu, Qijian Yi |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Endothelin Receptor Antagonists
medicine.medical_specialty Hypertension Pulmonary MEDLINE Hemodynamics 03 medical and health sciences 0302 clinical medicine Pharmacotherapy Text mining pulmonary arterial hypertension medicine Humans In patient 030212 general & internal medicine pulmonary arterial hypertension-specific drug therapy Intensive care medicine Antihypertensive Agents Sulfonamides Exercise Tolerance Phenylpropionates business.industry Eisenmenger syndrome Bosentan General Medicine Eisenmenger Complex Phosphodiesterase 5 Inhibitors medicine.disease Oxygen Pyridazines Position (obstetrics) Pyrimidines 030220 oncology & carcinogenesis Meta-analysis Prostaglandins business Systematic Review and Meta-Analysis Research Article |
| Zdroj: | Medicine |
| ISSN: | 1536-5964 |
| Popis: | Background: It is commonly reported a limitation of therapeutic strategy in Eisenmenger syndrome (ES) historically. This qualitative systematic review is conducted to evaluate the safety and efficacy of pulmonary arterial hypertension-specific drug therapy (PAH-SDT) for ES patients for a clinical therapeutic strategy based on evidence. Methods: PubMed, EMBASE, and the Cochrane Library databases have been systematically reviewed up to January 2019. Two reviewers independently conducted a literature search, quality evaluation, and data extraction. The occurrence of death, deterioration, and adverse events (AEs) has respectively been described as a count or percentage. Meta-analysis was conducted by Stata 15.1, and weighted mean differences (WMD) with 95% confidence intervals (CI) were recorded for continuous data. Randomized-effect model or fixed-effect model was applied according to the heterogeneity test. Results: Fifteen citations recruiting 456 patients associated with ES were eventually pooled, which involved 4 RCTs, 6 prospective studies, and 5 retrospective studies. Within the first year, it indicated PAH-SDT significantly ameliorated exercise capacity in 6-minute walk distance (6MWD) (I2 = 60.5%; WMD: 53.86 m, 95% CI [36.59, 71.13], P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|